Artificial intelligence is revolutionizing drug development, significantly reducing the time it takes to bring life-saving ...
A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer’s disease and other neudegenerative conditions. The corresponding study was published in ACS ...
The MarketWatch News Department was not involved in the creation of this content.-- Commercial sponsorship integrates EvE Bio's growing field--defining "pharmome" map - 385,572 ri ...
Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...
Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the next five years. Key factors driving this growth include the increasing ...
Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial ...
Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7 th Inflammasome Therapeutics Summit held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback